Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

NEW YORK & PARIS - 5th June, 2026 - Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist.

Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership.

During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built for Sanofi. These AI agents will work like intelligent assistants, autonomously performing complex tasks in drug research and development. They will be deployed through K Pro, with the aim of complementing and reinforcing Sanofi’s existing agentic AI capabilities.

K Pro combines multimodal patient data with specialized biological, agentic AI systems to support each stage of the pharmaceutical value chain, from early discovery through clinical development, while providing competitive intelligence, enabling faster, more informed, and more precise decisions.

Thomas Clozel, CEO and Co-founder of Owkin said:

“Building on our collaboration with Sanofi, this marks a shift toward truly embedded AI. Owkin believes that, with K Pro, Sanofi can further harness agentic systems within their own workflows, unlocking the full value of their data to accelerate better decisions across drug development.”

Emmanuel Frenehard, Chief Digital Officer at Sanofi said:

“Across Sanofi, we are continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle. By implementing purpose-built agentic systems into our workflows, we aim to empower our teams to operate with greater speed, depth, and confidence as we continue to work to deliver transformative outcomes for patients.”

K Pro’s development is part of Owkin’s mission to achieve Biological Artificial Superintelligence to unlock new therapeutic discoveries beyond the limits of human cognition alone. Owkin believes this technology will enable the pharmaceutical industry to address, and ultimately automate, some of the most complex challenges in R&D.